ERBB2 and prostate carcinoma: Among those few are many Fab fragments for HER2 (human epidermal growth factor receptor 2) targeting and the use of 124I-PSCA (Prostate Stem Cell Antigen)-specific minibody in order to assess the response to prostate cancer treatment using enzalutamide [9].